Omeros (NASDAQ:OMER) Shares Down 3.1% – What’s Next?

Omeros Co. (NASDAQ:OMER)’s stock price traded down 3.1% during mid-day trading on Monday . The company traded as low as $10.61 and last traded at $10.86. 44,701 shares were traded during mid-day trading, a decline of 90% from the average session volume of 459,604 shares. The stock had previously closed at $11.21.

Analyst Ratings Changes

OMER has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Rodman & Renshaw initiated coverage on Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. D. Boral Capital assumed coverage on Omeros in a research note on Monday, December 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Thursday, December 19th. Finally, StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Down 2.8 %

The company has a market cap of $573.13 million, a PE ratio of -4.28 and a beta of 2.01. The business’s 50 day moving average price is $8.57 and its 200-day moving average price is $5.73.

Institutional Trading of Omeros

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its holdings in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the period. MML Investors Services LLC raised its stake in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares in the last quarter. SPC Financial Inc. bought a new stake in Omeros in the third quarter worth about $77,000. SG Americas Securities LLC acquired a new stake in Omeros during the third quarter valued at approximately $80,000. Finally, AQR Capital Management LLC bought a new stake in Omeros during the second quarter worth approximately $105,000. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.